|
DBVT | Dbv Technologies S.a. |
|
|
DBVT | Dbv Technologies S.a. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.04 |
| Leverage | 52.17% |
| Market Cap | $ 1.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -73.1m |
| Margin | -1334.62% |
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.